Glaxo Flovent Diskus
Executive Summary
Fluticasone inhalational powder for Diskus delivery device will not be marketed until 2001, the company said following Sept. 29 approval of the product for maintenance of treatment of asthma as prophylactic therapy for patients four and above. The product is also indicated for patients requiring oral corticosteroid therapy for asthma. Fluticasone is currently marketed in a metered dose inhaler and in a Rotadisk dry powder inhaler. The Flovent Diskus NDA was submitted in March 1998 and has been "approvable" since March 31, 1999 (1"The Pink Sheet" Dec. 6, 1999, p. 8)